Skip to main content
Top
Published in: Endocrine Pathology 3/2007

01-09-2007

Molecular Genetic Events in Gastrointestinal and Pancreatic Neuroendocrine Tumors

Authors: Irina A. Lubensky, Zhengping Zhuang

Published in: Endocrine Pathology | Issue 3/2007

Login to get access

Abstract

Gastrointestinal and pancreatic neuroendocrine tumors originate from the cells of the diffuse endocrine system. Their molecular genetic mechanism of development and progression is complex and remains largely unknown, and they are different in genetic composition from the gastrointestinal epithelial tumors. The current literature suggests that multiple genes are involved in their tumorigenesis with significant differences for tumors of different embryological derivatives: foregut, midgut and hindgut. The MEN1 gene is involved in initiation of 33% of foregut gastrointestinal neuroendocrine tumors. 18q defects are present almost exclusively in mid/hindgut neuroendocrine tumors. X-chromosome markers are associated with malignant behavior in foregut tumors only. Analysis of poorly differentiated neuroendocrine carcinomas of any site demonstrates high chromosomal instability and frequent p53 alterations similar to other poorly differentiated carcinomas. Several factors played a limiting role in the molecular studies published to date: the tumors are rare and heterogeneous, it is difficult to predict their behavior and prognosis, and several different tumor classifications are used by the investigators in the studies. Future studies need to evaluate molecular genetic composition of large series of gastrointestinal and pancreatic neuroendocrine tumors of each specific tumor type. Understanding of specific genetic alterations characteristic for gastrointestinal and pancreatic neuroendocrine tumors might lead to their improved diagnosis, morphologic and molecular characterization and treatment.
Literature
1.
go back to reference Rindi G, Bordi C. Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 19:519–534, 2005.PubMedCrossRef Rindi G, Bordi C. Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 19:519–534, 2005.PubMedCrossRef
2.
go back to reference Lubensky IA. Endocrine Pancreas. In: LiVolsi VA, Asa S, eds. Endocrine Pathology. Philadelphia, London, Toronto: W. B. Saunders Co, pp. 205–235, 2002. Lubensky IA. Endocrine Pancreas. In: LiVolsi VA, Asa S, eds. Endocrine Pathology. Philadelphia, London, Toronto: W. B. Saunders Co, pp. 205–235, 2002.
3.
go back to reference Furth EE. Gastrointestinal Tract. In: LiVolsi VA, Asa S, eds. Endocrine Pathology. Philadelphia, London, Toronto: W. B. Saunders Co, pp. 2237–2260, 2002. Furth EE. Gastrointestinal Tract. In: LiVolsi VA, Asa S, eds. Endocrine Pathology. Philadelphia, London, Toronto: W. B. Saunders Co, pp. 2237–2260, 2002.
4.
go back to reference Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann N Y Acad Sci 1014:13–27, 2004.PubMedCrossRef Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann N Y Acad Sci 1014:13–27, 2004.PubMedCrossRef
5.
go back to reference Rindi G, Klöppel G, Alhman H, all other Frascati Consensus Conference participants, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401, 2006.PubMedCrossRef Rindi G, Klöppel G, Alhman H, all other Frascati Consensus Conference participants, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401, 2006.PubMedCrossRef
6.
go back to reference Kidd M, Modlin IM, Mane SM, et al. Utility of molecular genetic signatures in the delineation of gastric neoplasia. Cancer 106:1480–1488, 2006.PubMedCrossRef Kidd M, Modlin IM, Mane SM, et al. Utility of molecular genetic signatures in the delineation of gastric neoplasia. Cancer 106:1480–1488, 2006.PubMedCrossRef
7.
go back to reference Zikusoka MN, Kidd M, Latich, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 104:2292–309, 2005.PubMedCrossRef Zikusoka MN, Kidd M, Latich, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 104:2292–309, 2005.PubMedCrossRef
8.
go back to reference Bordi C, D’Adda T, Azzoni C, et al. Criteria for malignancy in gastrointestinal endocrine tumors. Endocr Pathol. (Review) 17(2):119–129, 2006, Summer.CrossRef Bordi C, D’Adda T, Azzoni C, et al. Criteria for malignancy in gastrointestinal endocrine tumors. Endocr Pathol. (Review) 17(2):119–129, 2006, Summer.CrossRef
9.
go back to reference Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404–407, 1997.PubMedCrossRef Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404–407, 1997.PubMedCrossRef
10.
go back to reference Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 57:4682–4686, 1997.PubMed Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 57:4682–4686, 1997.PubMed
11.
go back to reference Goebel SU, Heppner C, Burns L, et al. Genotype/phenotype correlation of MEN1 gene mutations in sporadic gastrinomas. J Clin Endocr Metab 85:116–123, 2000.PubMedCrossRef Goebel SU, Heppner C, Burns L, et al. Genotype/phenotype correlation of MEN1 gene mutations in sporadic gastrinomas. J Clin Endocr Metab 85:116–123, 2000.PubMedCrossRef
12.
go back to reference Rindi G, Villanacci V, Ubiali A, Scarpa A. Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn 1:323–333, 2001.PubMedCrossRef Rindi G, Villanacci V, Ubiali A, Scarpa A. Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn 1:323–333, 2001.PubMedCrossRef
13.
go back to reference Moore PS, Missiaglia E, Antonello D, et al. Role of disease-causing genes in sporadic pancreatic endocrine tumors: MENI and VHL. Genes Chromosomes Cancer 32:177–181, 2001.PubMedCrossRef Moore PS, Missiaglia E, Antonello D, et al. Role of disease-causing genes in sporadic pancreatic endocrine tumors: MENI and VHL. Genes Chromosomes Cancer 32:177–181, 2001.PubMedCrossRef
14.
go back to reference D’Adda T, Pizzi S, Azzoni C, et al. Different patterns of 11q allelic losses in digestive endocrine tumors. Hum Pathol 33:322–329, 2002.PubMedCrossRef D’Adda T, Pizzi S, Azzoni C, et al. Different patterns of 11q allelic losses in digestive endocrine tumors. Hum Pathol 33:322–329, 2002.PubMedCrossRef
15.
go back to reference Eubanks PJ, Sawicki MP, Samara GJ, et al. Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. Am J Surg 167:180–185, 1994.PubMedCrossRef Eubanks PJ, Sawicki MP, Samara GJ, et al. Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. Am J Surg 167:180–185, 1994.PubMedCrossRef
16.
go back to reference Chakrabarti R, Srivatsan ES, Wood TF, et al. Deletion mapping of endocrine tumors localizes a second tumor suppressor gene on chromosome band 11q13. Genes Chromosomes Cancer 22:130–137, 1998.PubMedCrossRef Chakrabarti R, Srivatsan ES, Wood TF, et al. Deletion mapping of endocrine tumors localizes a second tumor suppressor gene on chromosome band 11q13. Genes Chromosomes Cancer 22:130–137, 1998.PubMedCrossRef
17.
go back to reference D’Adda T, Keller G, Bordi C, Hoffler H. Loss of heterozygosity at 11q13–14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 79:671–677, 1999.PubMed D’Adda T, Keller G, Bordi C, Hoffler H. Loss of heterozygosity at 11q13–14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 79:671–677, 1999.PubMed
18.
go back to reference Libutti SK, Choyke PL, Alexander HR, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 128:1022–1028, 2000.PubMedCrossRef Libutti SK, Choyke PL, Alexander HR, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 128:1022–1028, 2000.PubMedCrossRef
19.
go back to reference Lubensky IA, Pack S, Ault D, et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153:223–231, 1998.PubMed Lubensky IA, Pack S, Ault D, et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153:223–231, 1998.PubMed
20.
go back to reference Chung DC, Smith AP, Louis DN, et al. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 100:404–410, 1997.PubMed Chung DC, Smith AP, Louis DN, et al. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 100:404–410, 1997.PubMed
21.
go back to reference Chung DC, Brown SB, Graeme-Cook F, et al. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res 58:3706–3711, 1998.PubMed Chung DC, Brown SB, Graeme-Cook F, et al. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res 58:3706–3711, 1998.PubMed
22.
go back to reference Moore PS, Orlandini S, Zamboni G, et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 84:253–262, 2001.PubMedCrossRef Moore PS, Orlandini S, Zamboni G, et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 84:253–262, 2001.PubMedCrossRef
23.
go back to reference Speel EJM, Scheidweiler AF, Zhao JM, et al. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas. Cancer Res 61:5186–5192, 2001.PubMed Speel EJM, Scheidweiler AF, Zhao JM, et al. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas. Cancer Res 61:5186–5192, 2001.PubMed
24.
go back to reference Muscarella P, Melvin WS, Fisher WE, et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res 58:237–240, 1998.PubMed Muscarella P, Melvin WS, Fisher WE, et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res 58:237–240, 1998.PubMed
25.
go back to reference Serrano J, Goebel S, Peghini P, et al. Alterations of the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 85:4146–4156, 2000.PubMedCrossRef Serrano J, Goebel S, Peghini P, et al. Alterations of the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 85:4146–4156, 2000.PubMedCrossRef
26.
go back to reference Bartsch DK, Kersting M, Wild A, Low frequency of p16INK4a alterations in insulinomas. Digestion 62:171–177, 2000.PubMedCrossRef Bartsch DK, Kersting M, Wild A, Low frequency of p16INK4a alterations in insulinomas. Digestion 62:171–177, 2000.PubMedCrossRef
27.
go back to reference Speel EJM, Richter J, Moch H, et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 155:1787–1794, 1999.PubMed Speel EJM, Richter J, Moch H, et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 155:1787–1794, 1999.PubMed
28.
go back to reference Rigaud G, Missiaglia E, Moore PS, et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 61:285–292, 2001.PubMed Rigaud G, Missiaglia E, Moore PS, et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 61:285–292, 2001.PubMed
29.
go back to reference Terris B, Meddeb M, Marchio M, et al. Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system. Genes Chromosomes Cancer 22:50–56, 1998.PubMedCrossRef Terris B, Meddeb M, Marchio M, et al. Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system. Genes Chromosomes Cancer 22:50–56, 1998.PubMedCrossRef
30.
go back to reference Pearce SH, Trump D, Wooding C, et al. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 45:195–200, 1996.CrossRef Pearce SH, Trump D, Wooding C, et al. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 45:195–200, 1996.CrossRef
31.
go back to reference Chung DC, Smith AP, Louis DN, et al. Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clin Endocrinol (Oxf) 47:523–528, 1997.CrossRef Chung DC, Smith AP, Louis DN, et al. Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clin Endocrinol (Oxf) 47:523–528, 1997.CrossRef
32.
go back to reference Wild A, Langer P, Ramaswamy A, Chaloupka B, Bartsch DK. A novel insulinoma tumor suppressor gene locus on chromosome 22q with potential prognostic implications. J Clin Endocrinol Metab 86:5782–5787, 2001.PubMedCrossRef Wild A, Langer P, Ramaswamy A, Chaloupka B, Bartsch DK. A novel insulinoma tumor suppressor gene locus on chromosome 22q with potential prognostic implications. J Clin Endocrinol Metab 86:5782–5787, 2001.PubMedCrossRef
33.
go back to reference Chung DC, Brown SB, Graeme-Cook F, et al. Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. J Clin Endocrinol Metab 85:4373–4378, 2000.PubMedCrossRef Chung DC, Brown SB, Graeme-Cook F, et al. Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. J Clin Endocrinol Metab 85:4373–4378, 2000.PubMedCrossRef
34.
go back to reference Chan AO, Kim SG, Bedeir A, et al. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22:924–934, 2003.PubMedCrossRef Chan AO, Kim SG, Bedeir A, et al. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22:924–934, 2003.PubMedCrossRef
35.
go back to reference House MG, Herman JG, Guo MZ, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 238:423–431, 2003discussion 431–432.PubMed House MG, Herman JG, Guo MZ, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 238:423–431, 2003discussion 431–432.PubMed
36.
go back to reference Dammann R, Schagdarsurengin U, Liu L, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22:3806–3812, 2003.PubMedCrossRef Dammann R, Schagdarsurengin U, Liu L, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22:3806–3812, 2003.PubMedCrossRef
37.
go back to reference Dammann R, Schagdarsurengin U, Strunnikova M, et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 18:665–677, 2003.PubMed Dammann R, Schagdarsurengin U, Strunnikova M, et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 18:665–677, 2003.PubMed
38.
go back to reference Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54:1556–1560, 1994.PubMed Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54:1556–1560, 1994.PubMed
39.
go back to reference Beghelli S, Pelosi G, Zamboni G, et al. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. J Pathol 186:41–50, 1998.PubMedCrossRef Beghelli S, Pelosi G, Zamboni G, et al. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. J Pathol 186:41–50, 1998.PubMedCrossRef
40.
go back to reference Yashiro T, Fulton N, Hara H, et al. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 114:758–763, 1993discussion 763–764.PubMed Yashiro T, Fulton N, Hara H, et al. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 114:758–763, 1993discussion 763–764.PubMed
41.
go back to reference Pavelic K, Hrascan R, Kapitanovic S, et al. Multiple genetic alterations in malignant metastatic insulinomas. J Pathol 177:395–400, 1995.PubMedCrossRef Pavelic K, Hrascan R, Kapitanovic S, et al. Multiple genetic alterations in malignant metastatic insulinomas. J Pathol 177:395–400, 1995.PubMedCrossRef
42.
go back to reference Ebrahimi SA, Wang EH, Wu A, et al. Deletion of chromosome 1 predicts prognosis in pancreatic endocrine tumors. Cancer Res 59:S311–315, 1999. Ebrahimi SA, Wang EH, Wu A, et al. Deletion of chromosome 1 predicts prognosis in pancreatic endocrine tumors. Cancer Res 59:S311–315, 1999.
43.
go back to reference Barghorn A, Komminoth P, Bachmann D, et al. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J Pathol 194:451–458, 2001.PubMedCrossRef Barghorn A, Komminoth P, Bachmann D, et al. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J Pathol 194:451–458, 2001.PubMedCrossRef
44.
go back to reference Barghorn A, Speel EJM, Farspour B, et al. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 158:1903–1911, 2001.PubMed Barghorn A, Speel EJM, Farspour B, et al. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 158:1903–1911, 2001.PubMed
45.
go back to reference Lohmann DR, Funk A, Niedermeyer HP, Haupel S, Hofler H. Identification of p53-gene mutations in gastrointestinal and pancreatic carcinoids by non-radioisotopic SSCA. Virchows Arch [B] 64:293–296, 1993.CrossRef Lohmann DR, Funk A, Niedermeyer HP, Haupel S, Hofler H. Identification of p53-gene mutations in gastrointestinal and pancreatic carcinoids by non-radioisotopic SSCA. Virchows Arch [B] 64:293–296, 1993.CrossRef
46.
go back to reference La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 429:323–333, 1996.PubMedCrossRef La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 429:323–333, 1996.PubMedCrossRef
47.
go back to reference Pizzi S, D’Adda T, Azzoni C, et al. Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours. J Pathol 196:401–407, 2002.PubMedCrossRef Pizzi S, D’Adda T, Azzoni C, et al. Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours. J Pathol 196:401–407, 2002.PubMedCrossRef
48.
go back to reference Missiaglia E, Moore PS, Williamson J, et al. Sex chromosome anomalies in pancreatic endocrine tumors. Int J Cancer 98:532–538, 2002.PubMedCrossRef Missiaglia E, Moore PS, Williamson J, et al. Sex chromosome anomalies in pancreatic endocrine tumors. Int J Cancer 98:532–538, 2002.PubMedCrossRef
49.
go back to reference Zhao J, Moch H, Scheidweiler AF, et al. Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 32:364–372, 2001.PubMedCrossRef Zhao J, Moch H, Scheidweiler AF, et al. Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 32:364–372, 2001.PubMedCrossRef
50.
go back to reference Furlan D, Cerutti R, Uccella S, et al. Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res 10:947–957, 2004.PubMedCrossRef Furlan D, Cerutti R, Uccella S, et al. Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res 10:947–957, 2004.PubMedCrossRef
51.
go back to reference Debelenko LV, Emmert-Buck MR, Zhuang Z, et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology 113:773–781, 1997.PubMedCrossRef Debelenko LV, Emmert-Buck MR, Zhuang Z, et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology 113:773–781, 1997.PubMedCrossRef
52.
go back to reference Debelenko LV, Zhuang Z, Emmert-Buck MR, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 57:2238–2243, 1997.PubMed Debelenko LV, Zhuang Z, Emmert-Buck MR, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 57:2238–2243, 1997.PubMed
53.
go back to reference Bordi C, Falchetti A, Azzoni C, et al. Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol 21:1075–1082, 1997.PubMedCrossRef Bordi C, Falchetti A, Azzoni C, et al. Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol 21:1075–1082, 1997.PubMedCrossRef
54.
go back to reference Pizzi S, Azzoni C, Bassi D, et al. Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer 98:1273–1282, 2003.PubMedCrossRef Pizzi S, Azzoni C, Bassi D, et al. Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer 98:1273–1282, 2003.PubMedCrossRef
55.
go back to reference D’Adda T, Candidus S, Bordi C, Hoffler H. Gastric neuroendocrine neoplasms: tumor clonality and malignancy associated large X-chromosomal deletions. J Pathol 189:394–401, 1999.PubMedCrossRef D’Adda T, Candidus S, Bordi C, Hoffler H. Gastric neuroendocrine neoplasms: tumor clonality and malignancy associated large X-chromosomal deletions. J Pathol 189:394–401, 1999.PubMedCrossRef
56.
go back to reference Toliat MR, Berger W, Ropers HH, Neuhaus P, Wiedenmann B. Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet 350:12231997.PubMedCrossRef Toliat MR, Berger W, Ropers HH, Neuhaus P, Wiedenmann B. Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet 350:12231997.PubMedCrossRef
57.
go back to reference Görtz B, Roth J, Krähenmann A, et al. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 154:429–436, 1999.PubMed Görtz B, Roth J, Krähenmann A, et al. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 154:429–436, 1999.PubMed
58.
go back to reference Zhao JM, de Krijger RR, Meier D, et al. Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids)-marked differences indicating diversity in molecular pathogenesis. Am J Pathol 157:1431–1438, 2000.PubMed Zhao JM, de Krijger RR, Meier D, et al. Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids)-marked differences indicating diversity in molecular pathogenesis. Am J Pathol 157:1431–1438, 2000.PubMed
59.
go back to reference Tonnies H, Toliat MR, Ramel M, et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridization. Gut 48:536–541, 2001.PubMedCrossRef Tonnies H, Toliat MR, Ramel M, et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridization. Gut 48:536–541, 2001.PubMedCrossRef
60.
go back to reference Kytola S, Hoog A, Nord B, et al. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 158:1803–1808, 2001.PubMed Kytola S, Hoog A, Nord B, et al. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 158:1803–1808, 2001.PubMed
61.
go back to reference Löllgen RM, Hessman O, Szabo E, Westin G, Akerström G. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer 92:812–815, 2001.PubMedCrossRef Löllgen RM, Hessman O, Szabo E, Westin G, Akerström G. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer 92:812–815, 2001.PubMedCrossRef
62.
go back to reference Lohmann D, Putz B, Reich U, et al. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol 142:907–915, 1993.PubMed Lohmann D, Putz B, Reich U, et al. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol 142:907–915, 1993.PubMed
63.
go back to reference Jakobovitz O, Nass D, De Marco L, et al. Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. J Clin Endocrinol Metab 81:3164–3167, 1996.PubMedCrossRef Jakobovitz O, Nass D, De Marco L, et al. Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. J Clin Endocrinol Metab 81:3164–3167, 1996.PubMedCrossRef
64.
go back to reference Vortmeyer AO, Lubensky IA, Merino M, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst 89:1448–1453, 1997.PubMedCrossRef Vortmeyer AO, Lubensky IA, Merino M, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst 89:1448–1453, 1997.PubMedCrossRef
65.
go back to reference Ubiali A, Benetti A, Papotti M, Villanacci V, Rindi G. Genetic alterations in poorly differentiated endocrine colon carcinomas developing in tubulo-villous adenomas: a report of two cases. Virchows Arch 439:776–781, 2001.PubMed Ubiali A, Benetti A, Papotti M, Villanacci V, Rindi G. Genetic alterations in poorly differentiated endocrine colon carcinomas developing in tubulo-villous adenomas: a report of two cases. Virchows Arch 439:776–781, 2001.PubMed
66.
go back to reference Rossi G, Bertolini F, Sartori G, et al. Primary mixed adenocarcinoma and small cell carcinoma of the appendix: a clinicopathologic, immunohistochemical, and molecular study of a hitherto unreported tumor. Am J Surg Pathol 28:1233–1239, 2004.PubMedCrossRef Rossi G, Bertolini F, Sartori G, et al. Primary mixed adenocarcinoma and small cell carcinoma of the appendix: a clinicopathologic, immunohistochemical, and molecular study of a hitherto unreported tumor. Am J Surg Pathol 28:1233–1239, 2004.PubMedCrossRef
Metadata
Title
Molecular Genetic Events in Gastrointestinal and Pancreatic Neuroendocrine Tumors
Authors
Irina A. Lubensky
Zhengping Zhuang
Publication date
01-09-2007
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 3/2007
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-007-9007-x

Other articles of this Issue 3/2007

Endocrine Pathology 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.